Evropska unija - slovenščina - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastična sredstva - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Evropska unija - slovenščina - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - limfom, mantle cell - antineoplastična sredstva - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Evropska unija - slovenščina - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - multiple myeloma - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Evropska unija - slovenščina - EMA (European Medicines Agency)

mitsubishi pharma europe ltd - kolestilan - hiperfosfatemija - zdravila za zdravljenje hiperkaliemije in hiperfosfatemije - zdravljenje hiperfosfatemije pri odraslih bolnikih s kronično ledvično boleznijo 5. stopnje, ki prejemajo hemodializo ali peritonealno dializo.

Evropska unija - slovenščina - EMA (European Medicines Agency)

bial - portela & ca, s.a. - eslikarbazepin acetat - epilepsija - antiepileptics, - zdravilo zebinix je indicirano kot dodatno zdravljenje pri odraslih, mladostnikih in otrocih, starih nad 6 let, z epilepticnimi napadi s sekundarno generalizacijo ali brez nje.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

alkaloid - int d.o.o. - lamotrigin - tableta - lamotrigin 50 mg / 1 tableta - lamotrigin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

alkaloid - int d.o.o. - lamotrigin - tableta - lamotrigin 25 mg / 1 tableta - lamotrigin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

alkaloid - int d.o.o. - lamotrigin - tableta - lamotrigin 100 mg / 1 tableta - lamotrigin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gsk d.o.o., ljubljana - lamotrigin - tableta - lamotrigin 50 mg / 1 tableta - lamotrigin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gsk d.o.o., ljubljana - lamotrigin - žvečljiva/disperzibilna tableta - lamotrigin 200 mg / 1 tableta - lamotrigin